Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics (NASDAQ: FATE), a clinical-stage biopharmaceutical company focused on iPSC-derived cellular immunotherapies for cancer and autoimmune diseases, has announced a new employee inducement award. On March 3, 2025, the company granted restricted stock units (RSUs) for 24,000 shares of common stock to one newly-hired non-executive employee.
The grant, approved by the Compensation Committee under the Company's Amended and Restated Inducement Equity Plan, complies with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over a four-year period, with 25% of shares vesting annually on each grant date anniversary, contingent on continuous employment.
Fate Therapeutics (NASDAQ: FATE), un'azienda biofarmaceutica in fase clinica focalizzata sulle terapie immunologiche cellulari derivate da iPSC per il cancro e le malattie autoimmuni, ha annunciato un nuovo premio di indennità per i dipendenti. Il 3 marzo 2025, l'azienda ha concesso unità azionarie vincolate (RSU) per 24.000 azioni ordinarie a un nuovo dipendente non esecutivo.
La concessione, approvata dal Comitato per la Compensazione nell'ambito del Piano di Indennità Azionaria Modificato e Ripristinato dell'azienda, è conforme alla Regola di Quotazione Nasdaq 5635(c)(4). Le RSU matureranno in un periodo di quattro anni, con il 25% delle azioni che maturano annualmente all'anniversario della data di concessione, subordinato a un impiego continuativo.
Fate Therapeutics (NASDAQ: FATE), una empresa biofarmacéutica en etapa clínica centrada en terapias inmunológicas celulares derivadas de iPSC para el cáncer y enfermedades autoinmunes, ha anunciado un nuevo premio de incentivo para empleados. El 3 de marzo de 2025, la empresa otorgó unidades de acciones restringidas (RSUs) por 24,000 acciones ordinarias a un nuevo empleado no ejecutivo.
La concesión, aprobada por el Comité de Compensación bajo el Plan de Indemnización de Capital Modificado y Restablecido de la Compañía, cumple con la Regla de Cotización de Nasdaq 5635(c)(4). Las RSUs se consolidarán durante un período de cuatro años, con el 25% de las acciones consolidándose anualmente en cada aniversario de la fecha de concesión, condicionado a la continuidad del empleo.
Fate Therapeutics (NASDAQ: FATE), 암 및 자가면역 질환을 위한 iPSC 유래 세포 면역 요법에 중점을 둔 임상 단계의 생명공학 회사가 새로운 직원 유인 보상을 발표했습니다. 2025년 3월 3일, 회사는 새로 고용된 비임원 직원에게 제한 주식 단위(RSU) 24,000주를 부여했습니다.
이 부여는 회사의 수정 및 재작성된 유인 자본 계획에 따라 보상 위원회에 의해 승인되었으며, Nasdaq 상장 규칙 5635(c)(4)에 부합합니다. RSU는 4년 동안 분할 지급됩니다, 각 부여일 기념일에 매년 25%의 주식이 지급되며, 지속적인 고용을 조건으로 합니다.
Fate Therapeutics (NASDAQ: FATE), une entreprise biopharmaceutique en phase clinique se concentrant sur les immunothérapies cellulaires dérivées d'iPSC pour le cancer et les maladies auto-immunes, a annoncé une nouvelle prime d'incitation pour les employés. Le 3 mars 2025, l'entreprise a accordé des unités d'actions restreintes (RSU) pour 24 000 actions ordinaires à un nouvel employé non cadre.
Cette attribution, approuvée par le Comité de Rémunération dans le cadre du Plan de Capital d'Incitation Modifié et Révisé de l'Entreprise, est conforme à la Règle de Cotation Nasdaq 5635(c)(4). Les RSU se libéreront sur une période de quatre ans, avec 25 % des actions se libérant chaque année à l'anniversaire de la date d'attribution, sous réserve d'un emploi continu.
Fate Therapeutics (NASDAQ: FATE), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf iPSC-abgeleitete zelluläre Immuntherapien für Krebs und Autoimmunerkrankungen konzentriert, hat eine neue Mitarbeiteranreizvergütung bekannt gegeben. Am 3. März 2025 gewährte das Unternehmen eingeschränkte Aktieneinheiten (RSUs) für 24.000 Aktien an einen neu eingestellten nicht-executiven Mitarbeiter.
Die Gewährung, die vom Vergütungsausschuss im Rahmen des überarbeiteten und neu gefassten Anreizkapitalplans des Unternehmens genehmigt wurde, entspricht der Nasdaq-Listing-Regel 5635(c)(4). Die RSUs werden über einen Zeitraum von vier Jahren fällig, wobei 25 % der Aktien jährlich am Jahrestag des Gewährungstags fällig werden, abhängig von einer kontinuierlichen Beschäftigung.
- None.
- None.
SAN DIEGO, March 04, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on March 3, 2025 the Company granted restricted stock units (RSUs) representing 24,000 shares of its common stock to one newly-hired non-executive employee. The grant was approved by the Compensation Committee of the Company’s Board of Directors and granted under the Company’s Amended and Restated Inducement Equity Plan as an inducement material to the new employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with
About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived natural killer (NK) cell and T-cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
Contact:
Christina Tartaglia
Precision AQ
212.362.1200
christina.tartaglia@precisionaq.com
FAQ
How many RSUs did Fate Therapeutics (FATE) grant in their March 2025 inducement award?
What is the vesting schedule for FATE's March 2025 inducement RSU grant?
Under which regulatory rule was FATE's March 2025 inducement grant approved?
What is the purpose of Fate Therapeutics' March 2025 inducement equity award?
